SGAM
Smith Group Asset Management Portfolio holdings
AUM
$1.53B
1-Year Return
38.67%
This Quarter Return
+9.9%
1 Year Return
+38.67%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$1.89B
AUM Growth
+$159M
(+9.2%)
Cap. Flow
+$41.8M
Cap. Flow
% of AUM
2.21%
Top 10 Holdings %
Top 10 Hldgs %
34.09%
Holding
355
New
45
Increased
117
Reduced
138
Closed
28
Top Buys
| 1 |
Capital One
COF
|
$39.1M |
| 2 |
Envista
NVST
|
$25.6M |
| 3 |
West Pharmaceutical
WST
|
$24M |
| 4 |
JPMorgan Chase
JPM
|
$23.4M |
| 5 |
Eaton
ETN
|
$16.4M |
Top Sells
| 1 |
Allstate
ALL
|
$23.8M |
| 2 |
Apple
AAPL
|
$22.3M |
| 3 |
Cadence Design Systems
CDNS
|
$21.7M |
| 4 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$20.7M |
| 5 |
Zebra Technologies
ZBRA
|
$17.1M |
Sector Composition
| 1 | Technology | 30.41% |
| 2 | Consumer Discretionary | 14.8% |
| 3 | Healthcare | 14.63% |
| 4 | Financials | 11.82% |
| 5 | Industrials | 10.44% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
301
Petrobras
PBR
$78.4B
| $6K | ﹤0.01% |
+740
| New | +$6K |
|
302
AT&T
T
$211B
| $6K | ﹤0.01% |
262
| – | – |
|
303
TG Therapeutics
TGTX
$5.02B
| $6K | ﹤0.01% |
120
-3,390
| -97% | -$170K |
|
|
LMNX
304
DELISTED
Luminex Corp
LMNX
| $6K | ﹤0.01% |
200
-6,000
| -97% | -$180K |
|
|
NVTA
305
DELISTED
Invitae Corporation
NVTA
| $5K | ﹤0.01% |
130
-3,900
| -97% | -$150K |
|
|
EGOV
306
DELISTED
NIC Inc
EGOV
| $5K | ﹤0.01% |
140
-4,200
| -97% | -$150K |
|
307
Emergent Biosolutions
EBS
$411M
| $5K | ﹤0.01% |
50
-1,390
| -97% | -$139K |
|
|
AMED
308
DELISTED
Amedisys
AMED
| $4K | ﹤0.01% |
15
-1,882
| -99% | -$502K |
|
309
CareDx
CDNA
$733M
| $4K | ﹤0.01% |
60
-1,590
| -96% | -$106K |
|
310
Insmed
INSM
$30.4B
| $4K | ﹤0.01% |
130
-3,900
| -97% | -$120K |
|
|
BHVN
311
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $4K | ﹤0.01% |
60
-1,590
| -96% | -$106K |
|
|
ALLK
312
DELISTED
Allakos
ALLK
| $3K | ﹤0.01% |
30
-930
| -97% | -$93K |
|
313
Apellis Pharmaceuticals
APLS
$3.54B
| $3K | ﹤0.01% |
80
-2,500
| -97% | -$93.8K |
|
314
FibroGen
FGEN
$48.1M
| $3K | ﹤0.01% |
3
-92
| -97% | -$92K |
|
315
Amicus Therapeutics
FOLD
$2.52B
| $3K | ﹤0.01% |
300
-13,148
| -98% | -$131K |
|
316
Ironwood Pharmaceuticals
IRWD
$188M
| $3K | ﹤0.01% |
230
-6,600
| -97% | -$86.1K |
|
317
PTC Therapeutics
PTCT
$4.6B
| $3K | ﹤0.01% |
70
-2,100
| -97% | -$90K |
|
|
RDFN
318
DELISTED
Redfin
RDFN
| $3K | ﹤0.01% |
50
-1,600
| -97% | -$96K |
|
319
Xencor
XNCR
$621M
| $3K | ﹤0.01% |
60
-1,700
| -97% | -$85K |
|
|
CCXI
320
DELISTED
ChemoCentryx, Inc.
CCXI
| $3K | ﹤0.01% |
60
-1,590
| -96% | -$79.5K |
|
321
Allogene Therapeutics
ALLO
$255M
| $2K | ﹤0.01% |
60
-1,900
| -97% | -$63.3K |
|
322
Heron Therapeutics
HRTX
$202M
| $2K | ﹤0.01% |
120
-3,600
| -97% | -$60K |
|
323
Inovio Pharmaceuticals
INO
$143M
| $2K | ﹤0.01% |
15
-433
| -97% | -$57.7K |
|
324
Regenxbio
RGNX
$496M
| $1K | ﹤0.01% |
40
-1,100
| -96% | -$27.5K |
|
|
ICPT
325
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $1K | ﹤0.01% |
30
-1,000
| -97% | -$33.3K |
|